The C. elegans neural editome reveals an ADAR target mRNA required for proper chemotaxis

  1. Sarah N Deffit
  2. Brian A Yee
  3. Aidan C Manning
  4. Suba Rajendren
  5. Pranathi Vadlamani
  6. Emily C Wheeler
  7. Alain Domissy
  8. Michael C Washburn
  9. Gene W Yeo  Is a corresponding author
  10. Heather A Hundley  Is a corresponding author
  1. Indiana University, United States
  2. University of California at San Diego, United States
  3. University of California, San Diego, United States

Abstract

ADAR proteins alter gene expression both by catalyzing adenosine (A) to inosine (I) RNA editing and binding to regulatory elements in target RNAs. Loss of ADARs affects neuronal function in all animals studied to date. Caenorhabditis elegans lacking ADARs exhibit reduced chemotaxis, but the targets responsible for this phenotype remain unknown. To identify critical neural ADAR targets in C. elegans, we performed an unbiased assessment of the effects of ADR-2, the only A-to-I editing enzyme in C. elegans, on the neural transcriptome. Development and implementation of publicly available software, SAILOR, identified 7,361 A-to-I editing events across the neural transcriptome. Intersecting the neural editome with adr-2 associated gene expression changes, revealed an edited mRNA, clec-41, whose neural expression is dependent on deamination. Restoring clec-41 expression in adr-2 deficient neural cells rescued the chemotaxis defect, providing the first evidence that neuronal phenotypes of ADAR mutants can be caused by altered gene expression.

Article and author information

Author details

  1. Sarah N Deffit

    Medical Sciences Program, Indiana University, Bloomington, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Brian A Yee

    Department of Cellular and Molecular Medicine, Stem Cell Program, Institute for Genomic Medicine, University of California at San Diego, La Jolla, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Aidan C Manning

    Medical Sciences Program, Indiana University, Bloomington, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Suba Rajendren

    Department of Biology, Indiana University, Bloomington, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Pranathi Vadlamani

    Medical Sciences Program, Indiana University, Bloomington, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Emily C Wheeler

    Department of Cellular and Molecular Medicine, Stem Cell Program, Institute for Genomic Medicine, University of California at San Diego, La Jolla, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Alain Domissy

    Department of Cellular and Molecular Medicine, Stem Cell Program, Institute for Genomic Medicine, University of California at San Diego, La Jolla, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Michael C Washburn

    Department of Biology, Indiana University, Bloomington, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Gene W Yeo

    Department of Cellular and Molecular Medicine, Stem Cell Program, Institute for Genomic Medicine, University of California, San Diego, La Jolla, United States
    For correspondence
    geneyeo@ucsd.edu
    Competing interests
    The authors declare that no competing interests exist.
  10. Heather A Hundley

    Medical Sciences Program, Indiana University, Bloomington, United States
    For correspondence
    hahundle@indiana.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9106-9016

Funding

American Cancer Society (RSG-15-051-RMC)

  • Heather A Hundley

Indiana Clinical and Translational Sciences Institute

  • Sarah N Deffit

National Science Foundation

  • Emily C Wheeler

National Institutes of Health (1F32GM119257-01A1)

  • Sarah N Deffit

National Institutes of Health (T32GM00866)

  • Emily C Wheeler

National Institutes of Health (HG004659)

  • Gene W Yeo

National Institutes of Health (NS075449)

  • Gene W Yeo

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2017, Deffit et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,118
    views
  • 429
    downloads
  • 35
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Sarah N Deffit
  2. Brian A Yee
  3. Aidan C Manning
  4. Suba Rajendren
  5. Pranathi Vadlamani
  6. Emily C Wheeler
  7. Alain Domissy
  8. Michael C Washburn
  9. Gene W Yeo
  10. Heather A Hundley
(2017)
The C. elegans neural editome reveals an ADAR target mRNA required for proper chemotaxis
eLife 6:e28625.
https://doi.org/10.7554/eLife.28625

Share this article

https://doi.org/10.7554/eLife.28625

Further reading

    1. Chromosomes and Gene Expression
    2. Neuroscience
    Robyn D Moir, Emilio Merheb ... Ian M Willis
    Research Article

    Pathogenic variants in subunits of RNA polymerase (Pol) III cause a spectrum of Polr3-related neurodegenerative diseases including 4H leukodystrophy. Disease onset occurs from infancy to early adulthood and is associated with a variable range and severity of neurological and non-neurological features. The molecular basis of Polr3-related disease pathogenesis is unknown. We developed a postnatal whole-body mouse model expressing pathogenic Polr3a mutations to examine the molecular mechanisms by which reduced Pol III transcription results primarily in central nervous system phenotypes. Polr3a mutant mice exhibit behavioral deficits, cerebral pathology and exocrine pancreatic atrophy. Transcriptome and immunohistochemistry analyses of cerebra during disease progression show a reduction in most Pol III transcripts, induction of innate immune and integrated stress responses and cell-type-specific gene expression changes reflecting neuron and oligodendrocyte loss and microglial activation. Earlier in the disease when integrated stress and innate immune responses are minimally induced, mature tRNA sequencing revealed a global reduction in tRNA levels and an altered tRNA profile but no changes in other Pol III transcripts. Thus, changes in the size and/or composition of the tRNA pool have a causal role in disease initiation. Our findings reveal different tissue- and brain region-specific sensitivities to a defect in Pol III transcription.

    1. Biochemistry and Chemical Biology
    2. Chromosomes and Gene Expression
    Ting-Wen Chen, Hsiao-Wei Liao ... Chung-Te Chang
    Research Article

    The mRNA 5'-cap structure removal by the decapping enzyme DCP2 is a critical step in gene regulation. While DCP2 is the catalytic subunit in the decapping complex, its activity is strongly enhanced by multiple factors, particularly DCP1, which is the major activator in yeast. However, the precise role of DCP1 in metazoans has yet to be fully elucidated. Moreover, in humans, the specific biological functions of the two DCP1 paralogs, DCP1a and DCP1b, remain largely unknown. To investigate the role of human DCP1, we generated cell lines that were deficient in DCP1a, DCP1b, or both to evaluate the importance of DCP1 in the decapping machinery. Our results highlight the importance of human DCP1 in decapping process and show that the EVH1 domain of DCP1 enhances the mRNA-binding affinity of DCP2. Transcriptome and metabolome analyses outline the distinct functions of DCP1a and DCP1b in human cells, regulating specific endogenous mRNA targets and biological processes. Overall, our findings provide insights into the molecular mechanism of human DCP1 in mRNA decapping and shed light on the distinct functions of its paralogs.